MedTrace Logo

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

NCT06336707 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1048

Last updated 2024-07-18

No results posted yet for this study

Summary

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6.

This is a phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of HS-20089 in combination with other antitumor agents (Adebrelimab with or without platinum; Bevacizumab with or without platinum) in subjects with advanced solid tumors.

Conditions

Interventions

DRUG

HS-20089

Intravenous infusion

DRUG

Adebrelimab

Intravenous infusion

DRUG

Bevacizumab

Intravenous infusion

DRUG

Cisplatin / carboplatin

Intravenous infusion

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-11
Primary Completion
2026-04-08
Completion
2028-04-08
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06336707 on ClinicalTrials.gov